GleamWall
中文EN

SKVI SKINVISIBLE, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1085277 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.8%
TTM net income YoY-111.2%
TTM EPS YoY—
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-2,193.7%
Net margin-4,898.2%
FCF margin—
EBITDA margin-2,097.8%

Returns

ROE—
ROA-829.6%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets9,592.8%
Debt / equity—
Current ratio0.01x
Interest coverage-0.81x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-759.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$20,000$20,000
Gross profit$20,000$20,000
SG&A expense$496,076$589,151
Operating income-$496,315-$589,589
Interest expense$572,249$669,438
Net income-$1.06M-$565,654
EBITDA-$476,076-$569,151
EPS (diluted)—-0.11
Weighted avg. shares (diluted)—5.06M
Balance sheet
Cash & equivalents$2,620$10,336
Receivables$5,000$5,000
Current assets$27,531$42,028
Intangibles$100,036$116,189
Total assets$127,567$158,217
Current liabilities$5.02M$3.66M
Total liabilities$10.39M$9.38M
Shareholders' equity-$10.26M-$9.22M
Shares outstanding5.40M5.32M
Cash flow statement
Operating cash flow-$38,410-$69,834
Capital expenditure$4,086$9,218
Free cash flow-$42,496-$79,052
Investing cash flow-$4,086-$9,218
Financing cash flow$34,780$88,500
Depreciation & amortization$20,239$20,438

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.